Stoke is pioneering a new way to treat the underlying cause of severe genetic diseases by precisely upregulating protein expression. We develop antisense oligonucleotide medicines that increase gene expression to treat genetic epilepsies and other severe monogenic diseases, including genetic conditions affecting the central nervous system, eye, liver and kidney. We believe our proprietary technology platform, Targeted Augmentation of Nuclear Gene Output, or TANGO, will allow us to deliver disease-modifying therapies in a highly precise, durable and controlled manner.
We at Stoke have come together with a unique approach to RNA science, and a fundamental belief that we can do something no one else has done. We are united in our authenticity and committed to being true to ourselves, to our colleagues, and to the people with severe genetic diseases who are counting on us. We are driven yet caring, fast-paced yet thoughtful, diverse and intentionally inclusive. Our values guide our work to upend convention — and the status quo — to deliver meaningful medicines for people who need them.